Article Text

Download PDFPDF
Commentary in response to 'Impact of the COVID-19 pandemic on the process and outcome of thrombectomy for acute ischemic stroke'
  1. Thabele M Leslie-Mazwi1,
  2. Ronil V Chandra2,3,
  3. Joshua A Hirsch4
  1. 1 Departments of Neurosurgery and Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA
  2. 2 Interventional Neuroradiology Unit, Monash Imaging, Monash Health, Melbourne, Victoria, Australia
  3. 3 Department of Medicine and Department of Imaging, Monash University, Melbourne, Victoria, Australia
  4. 4 Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts, USA
  1. Correspondence to Dr Thabele M Leslie-Mazwi, Department of Neurosurgery, Massachusetts General Hospital, Boston, MA 02114, USA; tleslie-mazwi{at}mgh.harvard.edu

Statistics from Altmetric.com

The current COVID-19 global pandemic could potentially affect emergent large vessel occlusion (ELVO) ischemic stroke1 through at least two mechanisms. The first is possible increased stroke incidence due to procoagulant effects of the virus or the immune response to it.2–5 The second, more tangible, is the effect on ELVO triage and treatment times, a phenomenon already reported for emergent care of myocardial infarction6 and recently for acute stroke care during COVID-19 disruption in France.7

On the JNIS website currently is a paper from the Chinese epicenter, focused on the second of these. The authors present a single-center experience during the height of the pandemic (total lockdown in Wuhan until the end of newly diagnosed cases) and compare time intervals and procedural outcomes to pre-pandemic cases. Importantly, this is distinct from confirmed and suspected COVID-19 patients undergoing thrombectomy. Those patients were transferred from the community directly to a sequestered hospital environment; their treatment and outcomes after stroke remain unknown. Only limited case series have been published to date about treatment of known COVID-19-positive patients with stroke.8 9 The current paper is focused instead on the impact of the required modifications in the processes for patients with ELVO during the COVID-19 pandemic. Delays were expected because of expanded patient evaluation and staff protection …

View Full Text

Footnotes

  • Twitter @JoshuaAHirsch

  • Contributors All authors contributed equally to the formulation and editing of the document.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Commissioned; externally peer reviewed.

  • Data availability statement Data are available upon reasonable request.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles